1. Cell Cycle/DNA Damage
    Epigenetics
    Autophagy
  2. Sirtuin
    Autophagy
  3. SRT 1720

SRT 1720 

Cat. No.: HY-10532
Handling Instructions

SRT 1720 is a selective activator of human SIRT1 with an EC1.5 of 0.16 μM, and shows less potent activities agaiinst SIRT2 and SIRT3 with EC1.5s of 37 μM and > 300 μM, respectively.

For research use only. We do not sell to patients.

SRT 1720 Chemical Structure

SRT 1720 Chemical Structure

CAS No. : 925434-55-5

Size Price Stock
5 mg USD 132 Ask For Quote & Lead Time
10 mg USD 216 Ask For Quote & Lead Time
50 mg USD 660 Ask For Quote & Lead Time
100 mg USD 900 Ask For Quote & Lead Time

* Please select Quantity before adding items.

Other In-stock Forms of SRT 1720:

Other Forms of SRT 1720:

Top Publications Citing Use of Products

    SRT 1720 purchased from MCE. Usage Cited in: Toxicol Lett. 2016 Dec 15;264:1-11.

    The HNF1α, FXR, Mrp2 and Bsep protein levels are decreased after EE administration and significantly increased by SRT1720 in a dose dependent manner, which is in accordance with the mRNA levels.

    SRT 1720 purchased from MCE. Usage Cited in: Hypertension. 2016 Nov;68(5):1191-1199.

    SRT1720 rescues the downregulation of SIRT1 activity and protein expression in the aortas of KL+/– mice. A, Representative Western blot bands of Acetyl-P53 and total P53 and the quantification of SIRT1 activity. Data are expressed as the ratio of acetyl-p53/total P53. B, Representative Western blot bands and quantitative analysis of SIRT1 protein expression in aortas. Protein expression is normalized to β-actin, and the relative expression calculated as the fold change relative

    View All Sirtuin Isoform Specific Products:

    • Biological Activity

    • Protocol

    • Purity & Documentation

    • References

    • Customer Review

    Description

    SRT 1720 is a selective activator of human SIRT1 with an EC1.5 of 0.16 μM, and shows less potent activities agaiinst SIRT2 and SIRT3 with EC1.5s of 37 μM and > 300 μM, respectively.

    IC50 & Target[1] [1]

    SIRT1

    0.16 μM (EC1.5)

    SIRT2

    37 μM (EC1.5)

    In Vitro

    SRT 1720 effectively decreases the acetylation of p53 in cells even in the absence of SIRT1, and this is attributed to inhibition of histone acetyltransferase p300[2].

    In Vivo

    SRT 1720 (10, 30, 100 mg/kg, p.o.) significantly reduces the hyperinsulinaemia after 4 weeks, partially normalizing elevated insulin levels similar to rosiglitazone treatment. SRT 1720 treatment significantly reduces fasting blood glucose to near normal levels in Lepob/ob mice[1]. SRT 1720 has ability to protect against the negative effects of diet-induced obesity in mice, and has a connection to metabolic adaptation in fatty acid and oxidative metabolism through downstream targets of SIRT1 such as PGC1α and FOXO1[2]. SRT 1720 (50-100 mg/kg, p.o.), during emphysema development attenuates elastase-induced airspace enlargement and lung function impairment as well as reduces arterial oxygen saturation in WT mice[3].

    Molecular Weight

    469.56

    Formula

    C₂₅H₂₃N₇OS

    CAS No.

    925434-55-5

    SMILES

    O=C(NC1=C(C=CC=C1)C2=CN3C(SC=C3CN4CCNCC4)=N2)C5=NC6=C(N=C5)C=CC=C6

    Shipping

    Room temperature in continental US; may vary elsewhere

    Storage

    Please store the product under the recommended conditions in the Certificate of Analysis.

    Solvent & Solubility
    In Vivo:
    • 1.

      SRT 1720 is prepared in 10% hydroxypropyl-beta-cyclodextrin in 500 mM phosphate, pH 7.0[4].

    References
    Animal Administration
    [1]

    Mice: Nine week old C57BL/6 male mice are fed a high fat diet (60% calories from fat) until their mean body weight reach approximately 40 g. The mice are then divided into test groups (6-10 per group). SRT1460 (100 mg/kg), SRT1720 (100 mg/kg), SRT501 (500 mg/kg) and rosiglitazone (5 mg/kg) are administered once daily via oral gavage. The vehicle used is 2% HPMC + 0.2% DOSS. Individual mouse body weights are measured twice weekly. At 2, 4, 6, 8 and 10 weeks of dosing a fed blood glucose measure is taken and after 5 weeks of treatment an IPGTT is conducted on all mice from each of the groups. After 10 weeks of treatment, an ITT is conducted. Statistical analysis is completed using the JMP program. Data are analyzed by a one way ANOVA with comparison to control using a Dunnett’s Test. A p value < 0.05 indicates a significant difference between groups.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    References
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name

     

    Salutation

    Applicant name *

     

    Email address *

    Phone number *

     

    Organization name *

    Country or Region *

     

    Requested quantity *

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    SRT 1720
    Cat. No.:
    HY-10532
    Quantity: